^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Beta radiation emitter

    Related drugs:
    3d
    Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Jun 2026 | Trial primary completion date: Oct 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)
    3d
    Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers (clinicaltrials.gov)
    P1, N=162, Recruiting, Novartis Pharmaceuticals | N=124 --> 162 | Trial completion date: Jun 2030 --> Jan 2031 | Trial primary completion date: Jun 2030 --> Jan 2031
    Enrollment change • Trial completion date • Trial primary completion date
    3d
    Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    3d
    Targeted β--Particle Plus Conversion and Auger-Electron Therapy with 161Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. (PubMed, J Nucl Med)
    The tumor-to-bone marrow absorbed dose ratio was in the same range for [161Tb]Tb-DOTA-LM3 as for [177Lu]Lu-DOTATOC. The administration of 1 GBq of [161Tb]Tb-DOTA-LM3 was safe for all patients, without relevant adverse events.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    3d
    The Current Status of Nuclear Medicine in Africa. (PubMed, J Nucl Med)
    177Lu-therapies are restricted to 7 countries, and the availability of [131I]MIBG remains limited...Sustained investment in facilities, training, and regulatory frameworks is essential to achieve equitable access to care. IAEA's regional anchor centers as part of the Rays of Hope initiative exemplifies strategic capacity building, collaboration, and knowledge sharing in the region.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Azedra (iobenguane I 131)
    4d
    Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI-Driven Biomarkers. (PubMed, Cancers (Basel))
    Lutetium-177-PSMA-617 has become the standard radioligand therapy for metastatic castration-resistant prostate cancer, whereas alpha-emitting agents remain under clinical investigation...Integrative models combining imaging, genomic, and liquid biopsy data pave the way toward precision oncology and personalized therapeutic decision-making. Advances in imaging and theragnostics are reshaping prostate cancer management, bridging the gap between molecular biology and clinical practice to enable precision oncology.
    Review • Journal
    |
    AR (Androgen receptor)
    |
    AR splice variant 7
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    4d
    A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (clinicaltrials.gov)
    P1, N=22, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P1 trial
    4d
    PROQURE-1: EBRT + Lu-PSMA for N1M0 Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Completed, The Netherlands Cancer Institute | N=24 --> 14 | Recruiting --> Completed
    Trial completion • Enrollment change
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    5d
    NCI-2023-03480: Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting | N=10 --> 6
    Enrollment closed • Enrollment change
    5d
    NeoRay: [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake (clinicaltrials.gov)
    P1/2, N=71, Completed, Advanced Accelerator Applications | Active, not recruiting --> Completed | N=51 --> 71 | Trial completion date: Dec 2026 --> Nov 2025 | Trial primary completion date: Nov 2025 --> Jan 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative
    |
    AAA603
    6d
    DUNP19: A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Radiopharm Theranostics, Ltd
    New P1 trial
    7d
    Exploratory Analysis of [68Ga]Ga-FAP-2286 PET/CT Quantitative Parameters for Predicting Response to [177Lu]Lu-FAP-2286 Therapy in Non-small Cell Lung Cancer. (PubMed, Clin Nucl Med)
    Quantitative parameters derived from [68Ga]Ga-FAP-2286 PET/CT are valuable predictors of [177Lu]Lu-FAP-2286 treatment efficacy in NSCLC patients. Dynamic monitoring of these metrics allows for early identification of treatment responses and supports personalized therapy strategies.
    Journal
    |
    FAP (Fibroblast activation protein, alpha)
    |
    lutetium Lu 177 rofapitide tetraxetan (AAA614)